Servier and Institut Curie extend duration and scope of partnership in fight against cancer
All the news from Servier Group
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases
Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
Dr Claude Bertrand, General Director of Research and Development at Servier
Servier and Neurochlore join forces to treat autism in children
Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance